NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, OpGen reported after the close of the market on Thursday that its preliminary fourth quarter revenues fell 24 percent from Q4 2015, even as full-year 2016 revenues rose 27 percent.

For the three months ended Dec. 31, 2016, OpGen expects revenues of $1.0 million, down from the $1.3 million the company reported a year ago. Full the full year, OpGen expects revenues of $4.0 million, up from $3.2 million in 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.